The PPAR-γ Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age

European Journal of Endocrinology

Volumn 162, Issue 1, 2010, Pages 49-52

  De Kort, Sandra W K ^a   Hokken Koelega, Anita C S ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GENOMIC DNA; GLUCOSE; GROWTH HORMONE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; HUMAN GROWTH HORMONE;

ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CAUCASIAN; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; SHORT STATURE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL FOR DATE INFANT; WEIGHT GAIN; CHILD; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; GROWTH DISORDER; GROWTH, DEVELOPMENT AND AGING; PRESCHOOL CHILD;

ALANINE; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MALE; POLYMORPHISM, GENETIC; PPAR GAMMA; PROLINE; WEIGHT GAIN;

EID: 73949159311     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0631     Document Type: Article

References (26)

1. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia 1999 42 1033-1049.
2. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L & Lander ES. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000 26 76-80.
3. Kilpelainen TO, Lakka TA, Laaksonen DE, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M & Laakso M. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Medicine and Science in Sports and Exercise 2008 40 25-33.
4. Jaquet D, Tregouet DA, Godefroy T, Nicaud V, Chevenne D, Tiret L, Czernichow P & Levy-Marchal C. Combined effects of genetic and environmental factors on insulin resistance associated with reduced fetal growth. Diabetes 2002 51 3473-3478.
5. Tonjes A, Scholz M, Loeffler M & Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006 29 2489-2497.
6. Masud S & Ye S. Effect of the peroxisome proliferator activated receptor-γ gene Pro12Ala variant on body mass index: a meta-analysis. Journal of Medical Genetics 2003 40 773-780.
7. Lindi V, Sivenius K, Niskanen L, Laakso M & Uusitupa MI. Effect of the Pro12Ala polymorphism of the PPAR-γ2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia 2001 44 925-926.
8. Ek J, Urhammer SA, Sorensen TI, Andersen T, Auwerx J & Pedersen O. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999 42 892-895.
9. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M & Hokken-Koelega A. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clinical Endocrinology 2001 54 243-251.
10. Leunissen RW, Oosterbeek P, Hol LK, Hellingman AA, Stijnen T & Hokken-Koelega AC. Fat mass accumulation during childhood determines insulin sensitivity in early adulthood. Journal of Clinical Endocrinology and Metabolism 2008 93 445-451.
11. van Dijk M, Bannink EM, van Pareren YK, Mulder PG & Hokken-Koelega AC. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls. Journal of Clinical Endocrinology and Metabolism 2007 92 160-165.
12. Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J, Odink RJ, Reeser M, Rongen-Westerlaken C, Stokvis-Brantsma WH, Waelkens JJ & Hokken-Koelega AC. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial. Clinical Endocrinology 2007 67 485-492.
13. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP & Wit JM. Continuing positive secular growth change in The Netherlands 1955-1997. Pediatric Research 2000 47 316-323.
14. Usher R & McLean F. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. Journal of Pediatrics 1969 74 901-910.
15. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M & Hokken-Koelega A. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. Journal of Clinical Endocrinology and Metabolism 1999 84 3064-3070.
16. de Kort SW, Willemsen RH, van der Kaay DC & Hokken-Koelega AC. The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children. Clinical Endocrinology 2009 71 65-73.
17. De Kort SW, Van Dijk M, Willemsen RH, Ester WA, Viet L, De Rijke YB & Hokken-Koelega AC. Cardiovascular risk factors in parents of short children born small for gestational age. Pediatric Research 2008 64 91-96.
18. Cutfield WS, Bergman RN, Menon RK & Sperling MA. The modified minimal model: application to measurement of insulin sensitivity in children. Journal of Clinical Endocrinology and Metabolism 1990 70 1644-1650.
19. Miller SA, Dykes DD & Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988 16 1215.
20. Verveke G & Molenberghs G. Linear Mixed Models for Longitudinal Data. Berlin: Springer-Verlag, 2001.
21. de Kort SW, Mook-Kanamori DO, Jaddoe VW & Hokken-Koelega AC. Interactions between TCF7L2 genotype and growth hormone-induced changes in glucose homeostasis in small for gestational age children. Clinical Endocrinology In press DOI: 10.1111/j.1365-2265.2009.03635.x.
22. Eriksson JG, Lindi V, Uusitupa M, Forsen TJ, Laakso M, Osmond C & Barker DJ. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 2002 51 2321-2324.
23. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H & Pedersen O. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001 44 1170-1176.
24. Stumvoll M, Wahl HG, Loblein K, Becker R, Machicao F, Jacob S & Haring H. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes 2001 50 876-881.
25. Buzzetti R, Petrone A, Caiazzo AM, Alemanno I, Zavarella S, Capizzi M, Mein CA, Osborn JA, Vania A & di Mario U. PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatric Research 2005 57 138-140.
26. Yliharsila H, Eriksson JG, Forsen T, Laakso M, Uusitupa M, Osmond C & Barker DJ. Interactions between peroxisome proliferator-activated receptor-γ2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. Journal of Hypertension 2004 22 1283-1287.